First Header Logo Second Header Logo

Connection

Thomas Wierzba to Clinical Trials as Topic

This is a "connection" page, showing publications Thomas Wierzba has written about Clinical Trials as Topic.
Connection Strength

0.462
  1. Barry E, Cassels F, Riddle M, Walker R, Wierzba T. Vaccines Against Shigella and Enterotoxigenic Escherichia coli: A summary of the 2018 VASE Conference. Vaccine. 2019 08 07; 37(34):4768-4774.
    View in: PubMed
    Score: 0.169
  2. Wierzba TF. Implications and measurement of herd protection (indirect effects) for enteric vaccine development. Vaccine. 2019 08 07; 37(34):4775-4777.
    View in: PubMed
    Score: 0.169
  3. Clemens J, Savarino S, Abu-Elyazeed R, Safwat M, Rao M, Wierzba T, Svennerholm AM, Holmgren J, Frenck R, Park E, Naficy A. Development of pathogenicity-driven definitions of outcomes for a field trial of a killed oral vaccine against enterotoxigenic Escherichia coli in Egypt: application of an evidence-based method. J Infect Dis. 2004 Jun 15; 189(12):2299-307.
    View in: PubMed
    Score: 0.059
  4. Bourgeois AL, Wierzba TF, Walker RI. Status of vaccine research and development for enterotoxigenic Escherichia coli. Vaccine. 2016 06 03; 34(26):2880-2886.
    View in: PubMed
    Score: 0.033
  5. Mani S, Wierzba T, Walker RI. Status of vaccine research and development for Shigella. Vaccine. 2016 06 03; 34(26):2887-2894.
    View in: PubMed
    Score: 0.033
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.